Notícias

Here’s what could happen to ESTC shares next.

For workers who have watched groceries, insurance, utilities and housing get steadily more expensive, there is one number that can feel strangely resistant to inflation: their salary. One man in his late 30s says that no matter how much experience...

The proliferation of man-made material circling the planet is raising concerns over potential collisions.

Investing.com -- Artificial intelligence is creating a growing memory bottleneck, with Bernstein analysts saying demand is spreading beyond high-bandwidth memory into conventional DRAM, NAND flash and storage.

The leader guided the EV maker through its IPO and raised billions but her sudden exit signals a massive shift in where Wall Street’s top talent is heading.

A slowdown in AI model development won't fix OpenAI's financial woes.

Following historic performance, here’s what could happen to CRWD shares next.

Nvidia faces potential new costs for its AI chips and data-center infrastructure.

T-Mobile is changing how it handles customer interactions at its locations.

The federal government will control 55% of the company's effective output via equity ownership and oil production.

The biggest risk after Anthropic’s IPO would be its “revenue quality,” which is a structural mismatch in the business that may be hidden by the current run-rate, says Dr. Chan Ahn, Founder and CEO of Tessera PE and a former...

Cloudflare just cleared the government's highest civilian security bar, giving it access to contracts it was previously locked out of entirely. Whether that clearance turns into the kind of compounding federal revenue Palantir built depends on a template that has worked exactly once so far.

What Zuckerberg planned for Meta employees this year was far more radical than what the company ever confirmed.

Investing.com -- Here are the biggest analyst moves in the area of artificial intelligence (AI) for this week.

Kevin Warsh just told the market that the Fed has been blaming the wrong culprit for inflation for decades, and if he is right, the playbook for rate hikes, growth stocks, and the entire AI capital cycle changes with it.

A blowout quarter sent shares soaring and made three Wall Street firms rethink what this stock is worth.

Mr. Wonderful hunts for Bounty deals and wears $29 Walmart jeans — and the inflation data shows exactly why even the wealthy are watching what they spend on everyday essentials.

Investing.com - U.S. inflation expectations remain anchored despite more than five years of above-target price pressures, according to a Goldman Sachs research note published on Monday.

The stock market's sluggish summer heads into September focused on the Fed's mid-month rate policy meeting.

Costco is making it easier for members to get some of its most popular items without setting foot inside a warehouse.

Investors’ intense focus on AI is at times adding to the might of a small club of Big Tech stocks with mega market values to potentially make or break a single trading session for the S 500.

History says SpaceX shareholders will lose money in the coming months.

Investing.com -- Networking is replacing raw computing power as the main constraint on artificial intelligence performance as AI systems grow larger and more complex, Citi analysts said following the second day of the Hot Chips conference.

On Friday, a federal appeals court blocked Kalshi from avoiding Nevada gaming oversight, intensifying a nationwide fight over who regulates the fast-growing prediction markets industry. Kalshi Faces Regulatory Setback as Courts Clash The 9th U.S. Circuit Court of Appeals ruled...

A multi-billion-dollar bet on the Louisiana coast could reshape how investors value the newly public rocket maker.

One stubborn forecast is drawing unusual heat across Wall Street.

Bank of America sees a differentiated opportunity in a breakthrough sleep apnea pill.

For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. The pharma industry is entering its biggest wave of patent expirations in decades. The world’s bestselling drug in 2025, Merck’s cancer immunotherapy Keytruda, loses U.S. patent protection in 2028, and nearly every pharma company has at least one blockbuster drug that will go off patent in the next five years.

Record $659M profit driven by strong tanker rates across vessel classes.

Marvell Technology (NasdaqGS:MRVL) reported strong quarterly results and raised near term and long term revenue guidance, yet the stock fell after the earnings release. The company lifted its fiscal 2027 and 2028 revenue outlook, pointing to building momentum in data center demand and AI related growth drivers. The post earnings share price reaction highlighted that investor expectations for AI exposure remain very high, even when companies report solid operational performance. For a...